Stay updated on Milademetan Safety in AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.

Latest updates to the Milademetan Safety in AML/MDS Clinical Trial page
- Check2 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded a dedicated Locations section listing California, Kansas, New York, and Texas sites; removed the separate California/Kansas/New York/Texas location entries and the HHS Vulnerability Disclosure link; updated the page revision to v3.3.3.SummaryDifference0.5%

- Check46 days agoChange DetectedThe page shows a new revision label: v3.3.2 replacing v3.3.1, a minor technical update that does not affect the study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page now displays an updated revision banner: Revision v3.3.1 replaces Revision v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check60 days agoChange DetectedRemoved the general government funding update notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check75 days agoChange DetectedThere are no substantive changes to the study content; only minor cosmetic and layout adjustments are visible across sections. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Milademetan Safety in AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.